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Abstract: Snakes, scorpions, and spiders are venomous animals that pose a threat to human
health, and severe envenomings from the bites or stings of these animals must be treated with
antivenom. Current antivenoms are based on plasma-derived immunoglobulins or immunoglobulin
fragments from hyper-immunized animals. Although these medicines have been life-saving for
more than 120 years, opportunities to improve envenoming therapy exist. In the later decades,
new biotechnological tools have been applied with the aim of improving the efficacy, safety, and
affordability of antivenoms. Within the avenues explored, novel immunization strategies using
synthetic peptide epitopes, recombinant toxins (or toxoids), or DNA strings as immunogens have
demonstrated potential for generating antivenoms with high therapeutic antibody titers and broad
neutralizing capacity. Furthermore, these approaches circumvent the need for venom in the
production process of antivenoms, thereby limiting some of the complications associated with
animal captivity and venom collection. Finally, an important benefit of innovative immunization
approaches is that they are often compatible with existing antivenom manufacturing setups. In this
review, we compile all reported studies examining venom-independent innovative immunization
strategies for antivenom development. In addition, a brief description of toxin families of medical
relevance found in snake, scorpion, and spider venoms is presented, as well as how biochemical,
bioinformatic, and omics tools could aid the development of next-generation antivenoms.
Keywords: animal envenoming; antivenom development; immunization; synthetic epitope;
recombinant toxin; DNA immunization; neutralization; omics technologies; bioinformatics;
high-density peptide microarray technology; snakebite envenoming; scorpion envenoming;
spider envenoming
Key Contribution: An exhaustive compilation of the studies exploring innovative immunization
strategies for antivenom development, mainly focusing on venom-independent approaches.
1. Introduction
Snakes, scorpions, and spiders belong to a diverse group of venomous animals capable of causing
severe envenomings through their bite or sting, which are considered a serious public health issue in
many parts of the world [1–3]. Of these, snakebite envenoming is considered as having the highest
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impact, causing approximately 1.8–2.7 million cases annually, leading to 81,000–138,000 deaths [4–6].
Furthermore, it has been estimated that scorpion stings are responsible for approximately 1.2 million
envenomings each year, of which more than 3250 people die [7], whereas no reliable epidemiological
data for spider bites is available in the literature.
Since the first reports on antivenom development in 1894 [8], parenteral administration of
plasma-derived antivenoms of animal origin has been the only specific therapeutic option for the
treatment of envenomings by animal bites and stings [3,9]. At present, several public and private
laboratories around the world manufacture such antivenoms. However, in some countries, these
products are not readily available or are unaffordable for the victims [10–12]. Limited availability and
affordability issues are, in part, a consequence of the laborious and costly procedure of the traditional
antivenom manufacturing process, which requires keeping venomous animals in captivity and milking
them to obtain their venoms [13–15]. Venom procurement becomes further complicated in cases where
animals deliver low amounts of venom or when the animals do not thrive in captivity [13,16].
Even though antivenoms have generally proven effective and have saved thousands of lives
worldwide, various intrinsic features from either the manufacturing process or the nature of
the antivenom may restrict their clinical efficacy. Antivenom production involves the repeated
immunization (for months to years) of large mammals (mostly horses and sheep), followed by
purification of the immunoglobulin G (IgG) antibodies from the hyper-immunized plasma. IgG
purification is typically carried out by salting-out procedures using either caprylic acid or ammonium
sulfate [9,14,17–19]. Additionally, most manufacturers produce F(ab’)2 antivenoms by introducing
a pepsin digestion step [20]. As a result, antivenoms consist of a mixture of both toxin-neutralizing
antibodies and antibodies against all other antigens that the immunized animal has come across
throughout its life, resulting in a low titer of therapeutically relevant antibodies [21,22]. CroFab [23],
an antivenom purified by affinity chromatography using snake venom coupled to a matrix, is the only
exception. However, affinity purification greatly increases production costs. Moreover, the toxicity of
some venoms largely depends on poorly immunogenic low molecular mass toxins. This discrepancy
between toxicity and immunogenicity generates an unbalanced antibody content in antivenoms,
with a major fraction of the antibodies targeting immunogenic, but non-toxic, high molecular mass
components, and a minor fraction of the antibodies targeting highly toxic, but poorly immunogenic
components [24–28].
In order to reduce the public health burden caused by bites or stings of venomous animals, current
biotechnological tools have been applied to improve antivenom production (reviewed in [29–31]).
One useful approach has focused on antivenom production independent of venom use. Here, several
modern immunization techniques have been explored, such as the utilization of synthetic peptide
epitopes, recombinant toxins (or toxoids), consensus toxins, and DNA strings. Apart from leaving
aside venom use and, consequently, the need to keep venomous animals in captivity, antivenom
production based on new immunization approaches is considered quite feasible, since it can readily be
adapted to current manufacturing platforms without introducing significant modifications. In addition,
new immunization approaches may offer the possibility of exclusively using clinically relevant toxins
for the immunization procedure, likely leading to a higher titer of therapeutically relevant antibodies
and an increased antivenom neutralizing capacity. Such higher titers might, in turn, possibly result in
safer products (with lower propensity to cause adverse reactions), as the total dosage of antibodies
(which are heterologous proteins) required for venom neutralization would be lower. Moreover, since
antivenoms obtained using novel immunization strategies do not differ in nature from traditional
antivenoms, regulatory approval processes should not restrain their introduction into the market.
However, despite these advantages, inherent batch-to-batch variation is still expected, as a consequence
of the dependence on the immune system of immunized production animals [32].
In this paper, we present a comprehensive overview of all studies testing innovative
venom-independent immunization strategies for antivenom development. Some examples of
alternative venom-dependent approaches are also included. In addition, a summary of the clinically
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most important toxin families in snake, scorpion, and spider venoms is presented, as well as how
complementary biochemical, bioinformatic, and omics tools can be exploited to design cutting-edge
immunization protocols. Novel approaches in the therapy of envenomings, such as the development of
toxin inhibitors based on aptamers, small molecules, or recombinant antibodies (or fragments thereof)
of human or camelid origin are beyond the scope of this review, and can be found elsewhere [32–37].
2. Clinically Important Toxin Families
Envenoming by snakes, scorpions, and spiders can result in a wide spectrum of pharmacological
effects, ranging from localized tissue damage to systemic toxicities. Characteristic toxic effects,
which vary depending on the particular venom, include edema, dermonecrosis, myonecrosis,
hemolysis, hemorrhage, alterations in coagulation and platelet function, nephrotoxicity, cytotoxicity,
and neurotoxicity [6,38,39]. These diverse pathological manifestations are a consequence of the
complex composition of venoms, constituted by a mixture of enzymatic and non-enzymatic peptidic
and proteinaceous toxins, as well as low molecular mass organic and inorganic components [38,40,41].
Not all venom components contribute to the overall venom toxicity. The clinically most relevant
toxins (in terms of lethality) can be determined with the Toxicity Score, a parameter that takes into
account both potency (median lethal dose, LD50) and abundance of the individual toxins [27,42].
Studies on the efficacy of antivenom in neutralizing key venom toxins have underscored a discrepancy
between toxicity and immunogenicity [24,27,43,44]. Many immunogenic venom components have
been shown to be irrelevant for the overall toxicity, while some highly toxic venom components
are poorly immunogenic, or even immunosuppressive [45], with existing antivenoms sometimes
being unable to effectively neutralize them [24,27,44]. Generally, immunogenicity correlates with the
molecular size of the toxin, with toxins of low molecular mass being less immunogenic compared
to high molecular mass components [24,27,43,44]. Knowledge on venom composition, toxicity of
particular components, and toxin immunogenicity is thus imperative for antivenom development.
Hence, the identification of the most relevant toxins in venoms of high medical impact is of paramount
relevance for the design of optimal mixtures of toxins for immunization. In the following, a brief
summary of the clinically most important snake, scorpion, and spider toxin families is presented.
2.1. Snake Venom Toxin Families
Despite the complexity of snake venoms, most of the medically relevant snake toxins have been
found mainly to belong to a handful of toxin families (Figure 1a) [46–48]. The clinically most important
toxin families include (i) three-finger toxins (3FTxs), (ii) phospholipases A2 (PLA2s), (iii) snake venom
metalloproteinases (SVMPs), and (iv) snake venom serine proteinases (SVSPs) [46]. Additionally,
(v) dendrotoxins will also briefly be presented due to their importance for the notorious mamba
species [49].
2.1.1. Three-Finger Toxins
3FTxs are found in the venoms of elapids (including sea snakes and terrestrial elapids), ‘colubrids’
(sensu lato), and few viperids [46]. These toxins are non-enzymatic polypeptides of typically 60–74
amino acid residues with a shared common scaffold of three β-stranded loops extending from a central,
hydrophobic core with four conserved disulfide bonds. Members of the family include the neurotoxic
α-toxins, κ-toxins, and muscarinic toxins that target muscle nicotinic cholinergic receptors (nAChRs),
neuronal nAChRs, and subtypes of muscarinic receptors, respectively [46]. Another class of 3FTxs
are the fasciculins, which inhibit the enzyme acetylcholinesterase, thus preventing acetylcholine from
being broken down, leading to its accumulation at the synapse. This interference of neuromuscular
inhibition induces fasciculations in muscles [46]. In addition, some elapid venoms contain 3FTxs,
which exert cytotoxic activity, hence causing tissue necrosis [50].
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Figure 1. 3D structures of representative toxins belonging to each clinically relevant toxin family. (a) 
Snake toxins. (b) Scorpion toxins. (c) Spider toxins. 3FTx, three-finger toxin; PLA2, phospholipase A2; 
SVMP, snake venom metalloproteinase; SVSP, snake venom serine proteinase; DTx, dendrotoxin; 
BaP1, Bothrops asper P-I-type metalloproteinase; AaV-SP-I, Agkistrodon actus serine proteinase I; AahII, 
Androctonus australis hector toxin II; Cn2, Centruroides noxius Hoffmann toxin 2; Smase I, Loxosceles 
laeta sphingomyelinase I; PDB ID, Protein Data Bank accession ID. Images were created using PyMOL 
(The PyMOL Molecular Graphics System, Version 2.2 Schrödinger, LLC). 
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2.1.2. Phospholipases A2
PLA2s are found in the venoms of Viperidae, Elapidae, and Colubridae (sensu lato) snakes [6].
The lengths of PLA2s v ry from 119–134 amino acids, and they share a common caffold of four
main helices with sev n intrachain disulfide bonds [51]. PLA2s exert a wide variety of t xic activities,
including myotoxicity and neurotoxicity, either dependent or independent of their catalytic activity [51,
52]. The toxicity is caused by an initial plasma membrane perturbation, which promotes a large
increase in the cytosolic Ca2+ concentration that leads to degenerative events, in luding impairment
of mitochondrial function. Some PLA2s target presynaptic nerve terminals in the perip eral nervous
system causing paralysis, whereas others target both the nervous and muscular systems, or act on
skeletal muscles. The latter cause irreversible muscle damage, which can induce systemic myotoxicity,
e.g., rhabdomyolysis with myoglobinuria, leading to acute kidney injury [51]. Venom PLA2s also
exert other activities, including inhibition of coagulation, intravascular hemolysis, and are strongly
pro-inflammatory [52].
2.1.3. Snake Venom Metalloproteinases
Zinc-depende t SVMPs are a major component of venoms in the snak family Viperidae, but
are also present in species of Colubridae (sensu lato) and Elapidae [53,54]. SVMPs can be divided into
three classes (P-I, P-II, and P-III), depending on their domain composition, with molecular masses
of 20–30 kDa, 30–60 kDa, and 60–100 kDa, respectively [54]. SVMPs induce local and systemic
hemorrhage by hydrolyzing components of the extracellular matrix, including collagen IV in the
basement membrane of capillary blood vessels [6,53]. Their cleavage of cell-cell junctions also promotes
the mechanical weakening of the microvessel wall, leading to extravasation [6]. In addition, SVMPs
cause myonecrosis, blistering, dermonecrosis, edema, and coagulopathies, and like PLA2s, induce
pain and inflammation [53].
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2.1.4. Snake Venom Serine Proteinases
SVSPs are found in venoms of the snake families Viperidae, Elapidae, and Colubridae
(sensu lato) [55]. The molecular masses of SVSPs vary between 26 and 67 kDa, depending on the
extent of glycosylation. SVSPs are trypsin-like enzymes, but with variable macromolecular substrate
specificity, acting by a common catalytic mechanism that includes a reactive serine residue [55]. SVSPs
interfere with blood coagulation, fibrinolysis, blood pressure, and platelet aggregation. SVMPs and
SVSPs act in the coagulation cascade, which can promote intravascular coagulation, but more often lead
to consumption coagulopathy [6]. The resulting incoagulability can contribute to systemic bleeding,
especially in venoms that simultaneously contain hemorrhagic toxins [6,55].
2.1.5. Dendrotoxins
Dendrotoxins are a family of toxins found among the Dendroaspis (mamba) snakes of the family
Elapidae. They consist of 57–60 amino acid residues crosslinked by three disulfide bonds, and show
structural homology to Kunitz-type serine protease inhibitors, albeit with different pharmacological
effects. Dendrotoxins exert their effects by blocking specific subtypes of voltage-dependent potassium
channels (Kv1 subfamily in neurons) that facilitate acetylcholine release at peripheral synapses,
resulting in an excitatory effect [49,56].
2.1.6. Minor Snake Venom Toxin Families
The toxin families discussed above represent the most important toxins in snake venoms from
the pathological and pathophysiological standpoint. However, snake venoms contain various other
proteins with lower contribution to venom toxicity. These minor snake venom protein families
include C-type lectin-like proteins, cysteine-rich secretory proteins (CRISPs), L-amino acid oxidases,
low molecular mass myotoxins (e.g., crotamine), vasoactive peptides, disintegrins, hyaluronidases,
natriuretic peptides, and sarafotoxins, among others, which are outside the scope of this paper and
have been described elsewhere [6,57].
2.2. Scorpion Venom Toxins
The clinically most relevant toxins in scorpion venoms are the scorpion α and β-toxins, both of
which are composed of 61–76 amino acid residues cross-linked by four disulfide bonds (Figure 1b).
These neurotoxins typically adopt a highly conserved three-dimensional structure comprising
an α-helix and three or four-stranded anti-parallel β-sheets with high chemical and thermal stability.
These toxins interact with multiple sites on voltage-gated sodium (NaV) channels [39,58], reflecting
their distinct pharmacological effects and mechanisms of action. Theα-toxins (also known as Old World
scorpion toxins) target neurotoxin binding site 3, which is localized on the extracellular surface of the
NaV channels and impede fast inactivation [58]. Consequently, this leads to prolonged depolarization
and excessive neuronal activity. The resulting sympathetic excitation and the endogenous release of
catecholamines can cause severe systemic effects, including myocardial injury, pulmonary edema,
and cardiogenic shock [39]. In contrast, the β-toxins (also known as New World scorpion toxins)
target neurotoxin binding site 4. Electrophysiological studies have revealed that the β-toxins cause
a hyperpolarizing shift in the voltage dependence of activation, thus lowering the threshold for action
potential firing [58]. Other neurotoxins in scorpion venoms act on voltage-gated potassium and
calcium channels. However, these toxins appear to be less important in human envenoming [39].
Severe envenoming is often caused by scorpions of the Buthidae family, nonetheless, in most cases
of scorpion stings, only localized pain and minimal systemic involvement follow [39]. Additionally,
scorpion venoms contain a range of enzymatic toxins, such as hyaluronidases, metalloproteinases,
and phospholipases [33].
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2.3. Spider Venom Toxins
In the majority of human envenoming cases, spider bites only cause minor effects, although
worldwide a few groups of spiders cause more significant effects and are thus medically significant.
These groups include (i) the widow spiders (Latrodectus spp.), (ii) the recluse spiders (Loxosceles spp.),
(iii) the Australian funnel-web spiders (Atrax spp. and Hadronyche spp.), and (iv) the armed or banana
spiders (Phoneutria spp.) from Brazil [59,60]. In the following, a brief description of representative
toxins from each group will be given.
2.3.1. α-Latrotoxin
α-Latrotoxin (α-LTX) is a 130 kDa neurotoxin found in Latrodectus venoms that appears
to be responsible for the clinical effects in humans resulting in the envenoming syndrome
‘latrodectism’ [60,61]. α-LTX induces neurotransmitter vesicle exocytosis via both Ca2+-dependent
and independent mechanisms [61]. Latrodectism is characterized by diaphoresis and pain developing
gradually and lasting for hours to days. In case of systemic envenoming, non-specific symptoms such as
nausea, vomiting, headache, and fatigue are common, but latrodectism is rarely life-threatening [59,60].
2.3.2. Sphingomyelinases D
Sphingomyelinases D (SMases D) are found in Loxosceles venoms and are considered the key
components involved in the development of dermonecrosis, the main manifestation of the cutaneous
form of loxoscelism. SMases D are 31–35 kDa enzymes that hydrolyze sphingomyelin in the outer
leaflet of mammalian plasma membranes, resulting in the formation of ceramide (Figure 1c) [62]. Local
effects of Loxosceles bites vary from small areas of erythema to progression of large areas of ulceration
and necrosis that can take months to heal. The often painless bite will in up to 10% of cases result
in severe systemic reactions (viscerocutaneous loxoscelism), including shock, complement-mediated
intravascular hemolysis, and renal failure [60,62].
2.3.3. δ-Hexatoxins
δ-Hexatoxins (δ-HXTXs) are homologous neurotoxins of about 4.8 kDa, responsible for the severe
envenoming symptoms in humans caused by bites of six different funnel-web species (Figure 1c) [63].
Severe systemic envenoming is rare, but the onset of life-threatening effects is rapid. Severe systemic
envenoming is characterized by neuromuscular excitation, including paraesthesia and fasciculations,
pulmonary edema and massive autonomic stimulation/excitation with generalized diaphoresis,
hypersalivation, hyperlacrimation, and hypertension. Without antivenom, further effects like
neuromuscular paralysis, coma, hypotension, and multi-organ failure might follow [59]. The δ-HXTXs
induce spontaneous repetitive firing and prolongation of action potentials by binding to receptor site 3
on NaV channels, slowing the inactivation of the channels and causing a hyperpolarizing shift of the
voltage dependence of activation [61].
2.3.4. Tx2-6
Tx2-6 is a small neurotoxin of about 5.3 kDa found in the venom of Phoneutria spiders [64],
that like the δ-HXTXs, slows inactivation of NaV channels and causes a shift in the hyperpolarized
direction of voltage dependence of activation [65]. A bite from the Phoneutria nigriventer spider
causes immediate local pain, diaphoresis, piloerection, and erythema. In systemic envenoming cases,
non-specific symptoms, such as nausea and vomiting, are observed, as well as autonomic effects,
such as tachycardia, hypertension, salivation, and priapism. It can in rare circumstances progress to
pulmonary edema [60].
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3. Innovative Venom-Independent Immunization Strategies
To avoid disadvantages associated with conventional antivenom production, while utilizing
existing manufacturing platforms, several researchers have studied the use of recombinant or synthetic
toxins and peptides, as well as DNA vaccination strategies to raise therapeutically relevant antibodies
via immunization procedures (Figure 2). By removing the current need for venom for antivenom
production, and hence for keeping collections of venomous animals, the laborious and potentially
dangerous work associated with animal handling can largely be circumvented for personnel [66].
However, venom will still be needed for antivenom quality control and research validation to
ensure that novel manufactured antivenoms have adequate efficacy. In the following, an exhaustive
compilation of novel venom-independent immunization approaches used in the snake, scorpion,
and spider antivenom research fields is provided.
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Figure 2. Schematic illustration of the most studied innovative immunization strategies explored for 
antivenom development. Based on the amino acid sequence of the toxin(s) of interest, short 
Figure 2. Schematic illustration of the ost studied innovative immunization strategies explored
for antivenom development. Based on the amino acid sequence of the toxin(s) of interest, short
immunogenic peptide(s) or full-length toxin(s), synthetically or recombinantly produced, can be
injected into animals. Immunization with the peptide(s) or toxin(s) will lead to a toxin-specific immune
response mediated by antibody-producing B lymphocytes. Alternatively, based on the DNA sequence(s)
of the toxin(s), a plasmid encoding the gene(s) of interest (GOI) can be transfected into animal cells
using a Gene Gun. Following transfection, the animal cells will translate the transcript derived from the
plasmid, generating a toxin able to raise a toxin-specific immune response with subsequent production
of antibodies by B lymphocytes.
3.1. Studies within Snake Antivenom Development
In terms of snake antivenom development using venom-independent immunization techniques,
variants of four different approaches have been utilized, summarized in chronological order in Table 1.
The first novel immunization approach concerns the injection of chemically synthesized epitopes
of toxins, usually based on epitope mapping studies or epitope prediction using bioinformatic software.
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The antisera raised using these discovered or predicted epitopes have been reported to achieve
both partial and complete neutralization in a range of studies. For instance, myotoxicity in mice
induced by Bothrops asper myotoxin II (a PLA2) was partially inhibited by antiserum raised against
a peptide comprising residues 115–129 (coupled to a diphtheria toxoid) [67], while another study
found prolongation of survival when mice immunized with three peptides from the C-terminus
of ammodytoxin A (a PLA2) were challenged with Crotalus durissus terrificus and Vipera ammodytes
snake venom [68]. In another study, complete neutralization of hemotoxicity was reported when
rabbits immunized with synthetic mutalysin II epitopes were challenged with Lachesis muta muta
snake venom [69]. Furthermore, in 1991, Cˇurin-Šerbec et al. immunized rabbits with four individual
synthetic peptides (residues 70–78, 106–113, 113–121, and 125–133) from ammodytoxin A conjugated
to keyhole limpet hemocyanin (KLH). Rabbit antiserum targeting peptide residues 106–113 completely
abolished lethality when naïve mice were challenged with ammodytoxin A, whereas antiserum against
residues 113–121 partially blocked toxicity [70]. In another study by Dolimbek and Atassi in 1996, mice
were immunized with three peptides from α-bungarotoxin (a 3FTx from Bungarus multicinctus venom),
which raised an immune response that was reported to neutralize up to 15 LD50s of α-bungarotoxin
injected intravenously in the immunized mice [71]. By further conjugating all three peptides to
ovalbumin, the protective capacity exceeded that of the mice immunized with native toxin by almost
2-fold. In a separate study from 2016, Cao and colleagues used the bioinformatic software DNAStar
and the online IEDB software (http://tools.immuneepitope.org/bcell/) to predict six linear B-cell
epitopes of three major toxins from Deinagkistrodon acutus snake venom. Murine antiserum raised
against a tandem protein of the six linear epitopes was able to protect naïve mice against 4 minimum
hemorrhagic doses (MHDs). Here, 1 MHD was defined as the dosage of snake venom required
to produce a 10 mm hemorrhagic spot on the visceral side of the back skin, 24 h after intradermal
injection [72].
A second novel immunization approach that has been investigated involves the use of full-length
synthetic or recombinant toxins as immunogens, and not only toxin epitopes. Compared to epitopes,
both in terms of size and structure, it is likely that these proteins serve as better immunogens due
to a closer similarity to the native toxins. A native-like structure is crucial for the generation of
antibodies able to recognize the native toxins. Furthermore, no prior epitope mapping study is
required. On the other hand, there is a risk of the toxins not folding correctly after chemical synthesis or
recombinant expression. One study reported complete neutralization of 2 LD50s of Bungarus candidus
snake venom injected intravenously in naïve mice, when venom was pre-incubated with murine
antiserum generated by immunization with α and β-neurotoxins (from α and β-bungarotoxin-based
RT-PCR and subsequent cloning and protein expression) as immunogens [73]. Furthermore, 3 LD50s
of a type I α-neurotoxin from Micrurus diastema was reported neutralized, when incubated with rabbit
antiserum raised against a recombinant α-neurotoxin (called rD.H) and injected intravenously in naïve
mice [74]. More recently, the investigation of a short-chain consensus α-neurotoxin was reported by de
la Rosa et al. As α-neurotoxins can be difficult to purify from Elapid snake venoms, the sequences
of 12 of the most toxic α-neurotoxins from venoms in the Elapidae family were used to generate
a recombinant consensus toxin, which was used to immunize rabbits. The consensus toxin was shown
to antagonize muscular nAChRs, and the raised immune antiserum was demonstrated to recognize the
native toxins from the venom of selected Elapid snakes (particular high titers against Micrurus elegans,
M. latifasciatus, and M. nigrocinctus snake venom) [75]. In comparison, the study by Guerrero-Garzón
and colleagues reported the generation of protective rabbit antiserum through immunization with
a recombinant D.H (rD.H) α-neurotoxin, capable of neutralizing the lethal activity of three Micrurus
neurotoxins (including rD.H) [74]. Considering the relatively low abundance and poor immunogenicity
of 3FTxs in Micrurus venoms [43,74,76], supplementing the immunization mixture of Micrurus snake
venoms with recombinant 3FTxs might enhance the therapeutic efficacy of the generated antivenom.
Thirdly, mimotopes (i.e., molecules mimicking the structure of toxin epitopes, but with
non-identical amino acid sequences) have been developed [77,78]. These mimotopes were developed by
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selecting peptides against immobilized monoclonal antibodies that have shown neutralizing capacity,
using k-mer peptide libraries and phage display technology. Despite the ability of the immobilized
antibodies to recognize different peptide-displaying phages, low sequence similarity existed between
the original toxin epitopes and the corresponding mimicked epitope [77,78]. Due to their non-toxic
nature, immunizing with epitopes or mimotopes has the advantage and opportunity to allow for
increased injection dosage, which may often lead to a more efficient immune response. However, a low
molecular mass may decrease immunogenicity, which again could be compensated for, by an increase
in injection dosage or by coupling the immunizing peptides with high molecular mass proteins.
Lastly, avoiding chemical synthesis or recombinant expression (with subsequent purification
steps), several studies have looked into the opportunity of using DNA immunization. Here, the
use of a Gene Gun to inject DNA (bound to gold or tungsten beads) into the animal that is to be
immunized has been reported. The injection targets epidermal cells in the abdominal region, which
then express and display epitopes for T helper 2 (TH2) cells to respond to [79–81]. From studies
exploring DNA immunization in the snake antivenom field, both antisera with lower [66,79,82] and
higher [81,83] neutralization capacities compared to conventional antisera have been reported. Wagstaff
and colleagues demonstrated that a mouse antiserum raised using an Echis ocellatus SVMP multiepitope
DNA string had better neutralization capacity in mice than an antiserum raised in rabbits by whole
E. ocellatus venom immunization [83]. Azofeifa-Cordero and co-workers reported partial neutralization
of hemorrhage induced by the rattlesnake Crotalus durissus durissus venom by immunizing with
DNA of a P-III type SVMP [84]. In a study by Pergolizzi et al. in 2004, it was demonstrated that
immunization by intravenous administration of either a modified α-cobratoxin plasmid alone or
delivered by a replication-deficient adenovirus vector conferred protection to mice (100% survival
rate), when challenged intravenously with 1 LD80 of α-cobratoxin from Naja kaouthia [85]. Interestingly,
one study reported the combined use of DNA injection followed by immunization with recombinant
toxins in mice. Here, 60% survival rate in naïve mice was achieved when mice were challenged
intraperitoneally with 3 LD50s of Micrurus corallinus snake venom pre-incubated with the generated
murine antiserum [66].
One of the challenges faced by DNA vaccines/immunization for human use has been insufficient
immune responses, despite success in pre-clinical models [86]. Although the antivenom field does
not rely on conferring an active vaccination of humans, DNA vaccination has great potential as
an immunization technique to obtain exogenous antibodies to be used for envenoming therapy [87].
However, when scaling up from murine models to larger production animals, high IgG titers
have failed to be achieved [87]. Some studies have tried to compensate for insufficient immune
response in production animals by priming with a DNA immunization and boosting with recombinant
proteins [66,88], thus lowering the required amount of protein antigen. DNA priming has also been
reported for HIV vaccination [89]. Alternatively, combining DNA immunization with appropriate
adjuvants also seems a feasible immunization approach for production of antivenom. A future step
in this direction may be inspired by development in other fields, where peptides or antibodies are
incorporated in liposomes for targeted payload delivery [90–94]. In this way, the efficacy of the immune
response may increase by directly targeting professional antigen-presenting cells (APCs) or T helper
cells, instead of having antigen presentation by abdominal epidermal cells targeted by Gene Gun
DNA injection.
By relying on DNA sequences rather than synthetically or recombinantly produced peptides
or toxins for immunization, less antigen is needed, as each DNA molecule can yield many antigen
molecules after translation. It may also prove less toxic for the production animals by lowering peak
exposure to toxins, thereby conferring the possibility of utilizing a high DNA immunization dosage,
potentially providing a stronger immune response [87]. In the future, this immunization approach
might also be further improved by adapting successful approaches from the fields of gene therapy and
DNA vaccination research.
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Table 1. Reported work on innovative venom-independent immunization strategies for snake antivenom development.
Authors & Year ImmunizationStrategy Species Target Toxin(s) Antivenom Challenge Toxin(s)
Effect(s)
Neutralized Ref.
Cˇurin-Šerbec et al., 1991 Synthetic epitope Vipera ammodytes Ammodytoxin A Rabbit antiserum Ammodytoxin A Lethality [70]
Cˇurin-Šerbec et al., 1994 Synthetic epitope
Crotalus durissus
terrificus,
Vipera ammodytes
Crotoxin and
ammodytoxin A Murine IgG, IgM Crotoxin
Prolonged
survival time [68]
Dolimbek and Atassi, 1996 Synthetic epitope Bungarusmulticinctus α-bungarotoxin Murine antiserum α-bungarotoxin Lethality [71]
Calderón et al., 1999 Synthetic epitope Bothrops asper Myotoxin II Murine antiserum Myotoxin II Myotoxicity [67]
Harrison et al., 2000 DNA Bothrops jararaca Jararhagin Murine antiserum B. jararaca venom Myotoxicity [79]
Harrison et al., 2002 DNA Bothrops jararaca Jararhagin Murine antiserum N/A Not Evaluated [80]
Pergolizzi et al., 2004 DNA Naja kaouthia α-cobratoxin Murine antiserum α-cobratoxin Lethality [85]
Wagstaff et al., 2006 DNA Echis ocellatus SVMPs Murine IgG E. ocellatus and Cerastescerastes venom Hemotoxicity [83]
Ferreira et al., 2006 Synthetic epitope Lachesis muta muta Mutalysin II Rabbit IgG Mutalysin II Hemotoxicity [69]
Azofeifa-Cordero et al., 2008 DNA Crotalus durissusdurissus P-III SVMP Murine antiserum C. d. durissus venom Hemotoxicity [84]
Leão et al., 2009 DNA Micrurus corallinus 3FTx and PLA2s Murine antiserum N/A Not evaluated [95]
Cardoso et al., 2009 Recombinantmimotope Bothrops neuwiedi Neuwiedase Murine antiserum N/A Not evaluated [78]
Arce-Estrada et al., 2009 DNA Bothrops asper P-II SVMP Equine antiserum B. asper and C. d.durissus venom Hemotoxicity [82]
Suntrarachun et al., 2010 Recombinant toxin Bungarus candidus α and
β-neurotoxins Murine antiserum B. candidus venom Lethality [73]
Machado de Avila et al., 2011 Syntheticmimotope Lachesis muta Mutalysin II Rabbit antiserum L. muta venom Hemotoxicity [77]
Ramos et al., 2016
DNA +
Recombinant
protein
Micrurus corallinus 3FTxs and PLA2 Murine antiserum M. corallinus venom Lethality [66]
Cao et al., 2016 Recombinantprotein
Deinagkistrodon
acutus
SVSPs, SVMPs
and PLA2s
Murine antiserum D. acutus venom Hemotoxicity [72]
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Table 1. Cont.
Authors & Year ImmunizationStrategy Species Target Toxin(s) Antivenom Challenge Toxin(s)
Effect(s)
Neutralized Ref.
Clement et al., 2016 Recombinant toxin Micrurus laticorallis
Cysteine-rich
neurotoxins
(Mlat1)
Rabbit antiserum M. laticorallis venom Not neutralizing [96]
Hasson, 2017 DNA Echis ocellatus Disintegrin Murine antiserum
Crotalus atrox, E.
ocellatus and Bitis arietans
venom
Hemotoxicity [81]
de la Rosa et al., 2018 Recombinant toxin
Acanthophis spp.,
Oxyuranus spp.,
Walterinnesia spp.,
Naja spp.,
Dendroaspis spp.
and Micrurus spp.
Type I
α-neurotoxins Rabbit antiserum N/A Not evaluated [75]
Guerrero-Garzón et al., 2018 Recombinant toxin Micrurus diastema Type I
α-neurotoxin D.H. Rabbit antiserum
rD.H, MlatA1, and
fraction F5 from M.
diastema venom
Lethality [74]
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3.2. Studies within Scorpion Antivenom Development
In the scorpion antivenom field, antivenom producers could benefit from being independent of
production animals for venom procurement, as this procedure is quite laborious due to involvement
of electrostimulation [16]. As with the snake antivenom field, synthetic epitopes have been
developed for immunization research (Table 2, see studies [97–103]). Several studies found varying
degrees of antibody-mediated protection against different antigen dosages. In 1986, Bahraoui et
al. immunized rabbits with a synthetic peptide of residues 50–59 of Androctonus australis hector
toxin II (AahII; a scorpion α-toxin) and used the generated antiserum to protect naïve mice against
an intracerebroventricular challenge of 14 LD50s of AahII, reporting 80% protection [97]. Interestingly,
the study also reported that conjugation of the synthetic peptide to bovine serum albumin (BSA)
resulted in antiserum that did not bind the free native toxins, highlighting that the choice of protein
carrier should be considered carefully, and that conjugation to carriers might not be a possibility
for all immunogens. Chávez-Olórtegui et al. reported partial protection of naïve mice against the
toxic fraction of Tityus serrulatus venom (TstG50), when subcutaneously injecting the pre-incubated
toxic fraction with antiserum derived from rabbits immunized with synthetic peptides derived from
the non-toxic protein TsNTxP [104]. Calderón-Aranda et al. immunized rabbits with 7 peptides
derived from Centruroides noxius toxin 2 (Cn2; a scorpion β-toxin) and reported 10–80% protection
in naïve mice after these were challenged intraperitoneally with 1 LD50 of Cn2 incubated with the
rabbit antiserum [98]. Interestingly, the latter study did not observe immunogenicity of all the utilized
epitopes, bringing attention to the need for careful epitope selection and validation [98]. Another
study reported full neutralization in naïve mice of up to 39.5 LD50s of Cn2 injected intraperitoneally
after incubating Cn2 with antiserum from rabbits immunized with synthetic epitopes of Cn2, where
also discontinuous epitopes were taken into account [99]. By 2002, Alvarenga and colleagues reported
the immunization of rabbits with four epitopes from TsNTxP and one epitope from the major lethal
component, TsIV, all conjugated to KLH. The rabbit antiserum was able to neutralize 13.5 LD50s of
TstG50-fractionated T. serrulatus venom (subcutaneous route) per mL antiserum in naïve mice [100].
Lastly, rabbits were immunized with an 18-residue peptide from a birtoxin-like N-terminus peptide
(conjugated to KLH), and the IgGs were purified and reported to neutralize up to 60 LD99 of Parabuthus
transvaalicus scorpion venom (intracerebroventricular route) per mL of IgG [101]. In general, these
studies highlight that when selecting epitopes for immunization, focusing on similarity between the
most toxic venom components may be highly beneficial. Other than homology, conjugation to KLH
seems to be beneficial for increasing the immunization dosages, which may lead to stronger immune
responses. This has also been achieved by conjugation of venom components to other protein carriers,
such as ovalbumin, BSA, diphtheria toxoid [67], and tetanus toxoid [105]. Lowered toxicity, allowing
for increased immunization dosages, can also be achieved by altering the non-epitopic residues, such
as it has been done with chimeric toxins, mimotopes, and retro-inverso peptides, as discussed in the
next section [98,106,107].
Several studies utilizing recombinant or synthetic toxins/peptides for immunization have
reported successful results (Table 2, see studies [106,108–120]). One study found various levels
of protection of naïve mice challenged with intraperitoneal or subcutaneous injections of 1–3 LD50s
of Cn2 from C. noxius Hoffmann scorpion venom, when pre-incubated with rabbit antiserum raised
against a recombinant Cn5 (a crustacean-specific toxin) [112]. Zenouaki and colleagues reported 66%
protection of mice challenged with 5 LD50s (intracerebroventricular route) of AahII from A. australis
hector venom after immunization with a chimeric toxin, where α-aminobutyric acid was utilized
to replace cysteines [106]. Mendes et al. reported up to 75% protection against 2 LD50s injected
subcutaneously in naïve mice, against T. serrulatus scorpion venom, when incubating the scorpion
venom with antiserum from immunized rabbits prior to injection into the mice. The rabbits were
immunized with recombinant Ts1 toxoids (Ts1 is also called TsVIII or Ts-γ) [114]. Protection of 100%
was furthermore observed when challenging naïve mice subcutaneously with 14 LD50s of native Ts1
after pre-incubation with the rabbit antiserum. In another study, rabbits were immunized with AahI,
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AahII, and AahIII fused to maltose-binding protein (MBP), yielding antiserum, which neutralized up
to 15 LD50s/mL (subcutaneous route), when incubating the toxic fraction (Aah-G50) of A. australis
hector venom with the rabbit antiserum prior to injection into naïve mice. This neutralization capacity
was equal to the commercial antivenom available at the time [110]. In the same study, a chimeric toxin
consisting of AahI-MBP-AahII was used for immunization of rabbits, but was reported not to bind
the native AahI or AahII, indicating that epitopes may lose their immunogenicity if fusion leads to
loss of their native conformation, once again highlighting the importance of native-like structures
of immunogens for generating antibodies with optimal neutralization capacity [110]. In 1997, 200
LD50s of AahII per mg of monoclonal antibody was neutralized in naïve mice (intracerebroventricular
route), when pre-incubated with purified IgGs from mouse hybridoma cells, where the mice had
been immunized with a synthetic AahII toxoid (with α-aminobutyric acid replacing cysteines) [108].
Furthermore, another study showed that by immunizing mice with a fusion protein of Bot III and
ZZ domains of staphylococcal protein A, the immunized mice were protected against 10 LD50s
(subcutaneous route) of the most lethal toxin, Bot III, from Buthus occitanus tunetanus scorpion
venom [111]. A study by Jiménez-Vargas and colleagues in 2017 found that antiserum raised against
recombinant fusion proteins of thioredoxin-enterokinase cleavage site-Cn2 (Thio-EK-Cn2), Thio-EK-C.
suffusus toxin II, and Thio-EK-C. limpidus toxin I or II could neutralize 3 LD50s of C. noxius, C.
limpidus, C. suffusus, C. tecomanus, C. elegans, and C. sculpturatus scorpion venom in naïve mice,
when pre-incubated with just 0.25 mL of rabbit antiserum and injected intraperitoneally [118]. Lastly, a
US patent was granted for the use of 71 gene sequences encoding various scorpion genes for potential
DNA immunization, immunization with the corresponding recombinant proteins, or immunoglobulin
purification purposes [113]. It is worth mentioning that DNA immunization has yet to be attempted in
the scorpion antivenom field.
From the above, it becomes evident that selecting which immunization strategy to use when
applying synthetic or recombinant peptides or toxins as immunogens for development of antiserum
can be difficult, as results are influenced by several factors. Neutralization capacity depends on the
specific IgG titer of the antiserum, which in turn depends on the quantity and immunogenicity of
the antigen used for immunization. In addition, the affinity of the antibodies towards the epitopes
definitely play a key role. Secondly, the chosen animal model and its intrinsic genetic variance should
also be considered. Thus, after optimizing the protocols in small animal species, it is relevant to
upscale the protocols to large animals used to manufacture antivenoms. Another factor that makes
comparison of antisera particularly challenging is the use of different antiserum volumes and lethal
toxin dosages. Standardization in how the protective assays are executed would greatly improve
comparability between different methods.
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Table 2. Reported work on innovative venom-independent immunization strategies for scorpion antivenom development.
Authors & Year ImmunizationStrategy Species Target Toxin(s) Antivenom
Challenge
Toxin(s)
Effect(s)
Neutralized Ref.
Bahraoui et al., 1986 Synthetic epitope Androctonus australishector Toxin II (AahII) Murine antiserum AahII Lethality [97]
Devaux et al., 1993 Synthetic epitope Androctonus australishector Toxin II (AahII) Rabbit antiserum N/A N/A [103]
Calderón-Aranda et al., 1995 Synthetic epitope Centruroides noxius Cn2 Rabbit and murineantisera Cn2 Lethality [98]
Bouhaouala-Zahar et al., 1996 Recombinant toxin Buthus occitanustunetanus α-toxin Murine antiserum Bot and AaHG Lethality [121]
Devaux et al., 1997 Synthetic peptide Androctonus australishector Toxin II (AahII) Murine IgG AahII Lethality [108]
Zenouaki et al., 1997 Synthetic peptide Androctonus australishector Toxin II (AahII) Rabbit antiserum AahII Lethality [106]
Calderón-Aranda et al., 1999 Synthetic epitope Centruroides noxius Cn2 Rabbit and murineantisera Cn2 Lethality [99]
Guatimosim et al., 2000 Recombinant toxoid Tityus serrulatus TsNTxP Rabbit antiserum T. serrulatus venom Lethality [109]
Gazarian et al., 2000 Mimotopes Centruroides noxiusHoffmann Noxiustoxin Murine antiserum N/A N/A [122]
Chávez-Olórtegui et al., 2001 Synthetic epitope Tityus serrulatus TsNTxP Rabbit antiserum TstG50 Lethality [104]
Legros et al., 2001 Recombinant toxin Androctonus australishector
AahI, AahII and
AahIII (α-toxins)
Rabbit and murine
antisera AaH-G50 Lethality [110]
Benkhadir et al., 2002 Recombinant toxin Buthus occitanustunetanus Bot III (α-toxin) Murine antiserum
B. occitanus
tunetanus venom Lethality [111]
Alvarenga et al., 2002 Synthetic epitope Tityus serrulatus TsNTxP and TsIV Rabbit antiserum TstG50 Lethality [100]
Garcia et al., 2003 Recombinant toxin Centruroides noxiusHoffmann
Cn5 and
sub-fraction Rabbit antiserum Cn2 Lethality [112]
Inceoglu et al., 2006 Synthetic epitope Parabuthus transvaalicus Birtoxin Rabbit polyclonalIgG
P. transvaalicus
venom Lethality [101]
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Authors & Year ImmunizationStrategy Species Target Toxin(s) Antivenom
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Toxin(s)
Effect(s)
Neutralized Ref.
Corona Villegas et al., 2008 Recombinant toxin Centruroides spp.
Cex1-13, Cll3-8,
Cn4b, Cn10b, Ce3,
Ce5-7, Ce13(b),
Cg1-3, CsEv1-3,
CsEV8-9, CsE1x,
CsEIa, CexErg1-4,
Cll Erg1-4, Cn
Erg3-5, CeErg1-3,
CgErg1-3,
CsErg1-5
Rabbit antiserum Cn2 Lethality [113]
Mendes et al., 2008 Recombinant toxin Tityus serrulatus Ts1 Rabbit antiserum Tst1 and T.serrulatus venom Lethality [114]
Hernández-Salgado et al., 2009 Recombinant toxinand toxoid
Centruroides suffusus
suffusus CssII Rabbit antiserum
CssII, Cn2, and C.
suffusus suffusus
venom
Lethality [115]
García-Gómez et al., 2009 Recombinant toxin Parabuthus granulatus Pg8 Murine antiserum Pg8 and P.granulatus venom Lethality [116]
Duarte et al., 2010 Synthetic epitope Tityus serrulatus TsNTxP Murine antiserum T. serrulatus venom Lethality [102]
Eskandari et al., 2014 Recombinant toxin Mesobuthus eupeus BMK neurotoxin Murine antiserum N/A Not evaluated [117]
Uawonggul et al., 2014 Recombinant toxin Heterometrus laoticus Heteroscorpine-1(HS-1) Murine antiserum H. laoticus venom Paralysis [120]
Jiménez-Vargas et al., 2017 Recombinant toxin Centruroides spp. Cn2, Css2, Cll1,and Cll2
Murine and rabbit
antisera
C. noxius, C.
suffusus, C.
limpidus, C. elegans,
C. tecomanus, and
C. sculpturatus
venom
Lethality [118]
Safari Foroushani et al., 2018 Recombinant toxoid Hemiscorpius lepturus rPLD1 Murine antiserum rPLD1 and H.lepturus venom Lethality [119]
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3.3. Studies within Spider Antivenom Development
Production of spider antivenom stands to greatly benefit from innovative immunization
approaches, as sufficient amounts of venom are hard to procure due to animal maintenance and
laborious venom extraction by electrostimulation [123–125]. In this antivenom field, synthetic
toxins [126], recombinant toxins [124–135], synthetic epitopes [107,136,137], and a synthetic
mimotope [138] have been used as venom-independent immunization techniques for spider antivenom
development. An overview of the different studies is presented in Table 3.
Several studies have reported partial neutralization when utilizing synthetic or recombinant
toxins for immunization. Successfully raised antibody responses have yielded antisera, which were
tested against venoms or native toxins at different dosages of venom/toxin. For instance, Felicori et al.
produced the recombinant dermonecrotic protein I (rLiD1) from Loxosceles intermedia and utilized it
as an immunogen in mice. A protection of 75% was reported when the immunized mice were later
challenged subcutaneously with 2.5 LD50s of rLiD1 [129]. Conversely, Magalhães et al. reported a 65%
reduction in inflammation and almost complete abolishment of dermonecrosis in naïve rabbits after
incubation of Loxosceles gaucho spider venom with rabbit antiserum, raised against a recombinant
phospholipase D (LgRec1), natively from L. gaucho spider venom [124]. More studies report full
neutralization of Loxosceles sp. venom [127,128,134,139], of which one study reported the development
of a more effective antiserum than an existing commercial antivenom on the spider antivenom market.
In this study, the antiserum was raised against a sphingomyelinase D in horses and tested in rabbits
challenged with L. intermedia, L. laeta, and L. gaucho spider venom, demonstrating neutralization
capacity [130].
In 2009, Comis and colleagues reported the use of a synthetic robustoxin from Atrax robustus
venom, which had been conjugated to KLH and chemically deactivated by preventing disulfide
bridge formation, as an immunogen in Macaca fascicularis monkeys. After 15 weeks, the immunized
monkeys survived a subsequent challenge of 50 µg/kg of A. robustus spider venom [126]. Furthermore,
Oliveira et al. evaluated the utilization of transgenic mice (engineered to have human MHC class
II) for immunization purposes, where the collected murine antisera raised against recombinant
sphingomyelinase D (rLid1) were able to inhibit 87% of edema and to neutralize dermonecrosis
and hemotoxicity in naïve rabbits [135].
In studies that utilized synthetic epitopes or mimotopes for immunization, mostly the immunized
animals were challenged with venom or native toxins [107,125,137,138]. In one of these studies,
Fischer and colleagues reversed the primary sequence of robustoxin from A. robustus venom and
inverted all the chiral centers, yielding a proteolysis-resistant peptide that could be administered
orally or intraperitoneally. This method was shown to generate an immune response that saved 7
out of 8 immunized mice [107]. Interestingly, in 2011, de Moura et al. observed that the epitope of
LiD1 recognized by a previously reported monoclonal antibody could not be identified by a SPOT
epitope-scan. By screening a peptide library via phage display, de Moura et al. found a mimotope
mimicking a discontinuous epitope [138]. The mimotope was recognized by the monoclonal antibody
and utilized for immunization by liposomal delivery (cholesterol and phosphatidylcholine), which
generated an immune response in rabbits. The immunized rabbits were subsequently challenged
with 10 µg of L. intermedia spider venom. Here, 60% dermonecrotic protection, 80% protection against
hemorrhage, and higher protection against edema than rabbits immunized with the L. intermedia spider
venom was reported [138]. More studies have utilized discontinuous epitopes as well [77,99,126,131,
140].
Three studies by Mendes, Figueiredo, Lima, and colleagues in 2013, 2014, and 2018, respectively,
report the usage of a multiepitopic protein for immunization, of which at least one epitope
is discontinuous [125,131,132]. This multiepitopic protein protected immunized mice against
an intraperitoneal challenge of 2.5 LD50s of L. intermedia spider venom [125]. The multiepitopic
approach proved to generate antiserum with equal neutralization capacity of L. intermedia spider
venom, as immunization with the recombinant LiD1 toxin alone, except for edema neutralization [131].
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Future studies will show if the approach can be utilized to incorporate epitopes from toxins across
several spider species and see if they can yield a protective antiserum against the chosen species [125].
This latter approach could, in the future, be attempted in other antivenom fields. Perhaps, by increasing
the size of the recombinant protein, immunogenicity of the individual epitopes could be increased.
However, a possible obstacle in designing multiepitopic proteins may be ensuring proper epitope
folding, and here, linker length might play an essential role [141]. As with the scorpion antivenom
field, the spider antivenom development field has yet to explore DNA immunization.
The success of immunizing with recombinant toxins to generate antivenom seems to be
determined by the immunogenicity of the immunogen [136], immunization dosages (linked to toxicity),
and careful selection of epitopes, which is critical for immunization [136]. Likewise, homology to other
toxins in the same venom seems to be important for high neutralization capacity [101]. In order to
increase antiserum efficacy and cross-reactivity to closely related toxins from other species, selecting
epitopes with high homology to such other toxin components is important [101,109]. However,
the utilization of consensus toxins could be a better way to ensure cross-reactivity across homologous
toxins, regardless of evolutionary relatedness [75].
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Table 3. Reported work on innovative venom-independent immunization strategies for spider antivenom development.
Authors & Year ImmunizationStrategy Species Target Toxin(s) Antivenom Challenge Toxin(s)
Effect(s)
Neutralized Ref.
Fernandes Pedrosa et al., 2002 Recombinant toxin Loxosceles laeta Smase I Rabbit antiserum rSmase I and L. laetavenom Dermonecrosis [139]
Araujo et al., 2003 Recombinant toxin Loxosceles intermedia Dermonecrotictoxin Murine antiserum L. intermedia venom
Dermonecrosis
and lethality [127]
Tambourgi et al., 2004 Recombinant toxin Loxosceles intermedia Sphingomyelinases Rabbit antiserum N/A N/A [123]
Olvera et al., 2006 Recombinant toxin
Loxosceles reclusa,
Loxosceles boneti,
Loxosceles laeta
Sphingomyelinase
D
Rabbit antiserum
and equine F(ab’)2
rSMD, L. reclusa, L.
boneti and L. laeta venom Lethality [128]
Felicori et al., 2006 Recombinant toxin Loxosceles intermedia Dermonecrotictoxin LiD1 Murine antiserum L. intermedia venom Lethality [129]
Fischer et al., 2007 Synthetic epitope Atrax robustus Robustoxin Murine antiserum A. robustus venom Lethality [107]
de Almeida et al., 2008 Recombinant toxin
Loxosceles intermedia,
Loxosceles laeta and
Loxosceles gaucho
Sphingomyelinase
D Equine antiserum
L. intermedia, L. laeta,
and L. gaucho venom Dermonecrosis [130]
Felicori et al., 2009 Synthetic epitope Loxosceles intermedia Dermonecrotictoxin LiD1 Rabbit IgGs LiD1
Dermonecrosis,
hemotoxicity, and
edema
[136]
Comis et al., 2009 Synthetic toxin Atrax robustus Robustoxin Monkey antiserum A. robustus venom Lethality [126]
Dias-Lopes et al., 2010 Synthetic epitope Loxosceles intermedia Dermonecrotictoxin LiD1
Rabbit and murine
antisera
rLiD1 and L. intermedia
venom
Dermonecrosis,
hemotoxicity, and
lethality
[137]
Chaim et al., 2011 Recombinanttoxoid Loxosceles intermedia
Dermonecrotic
toxin LiD1 Rabbit antiserum N/A N/A [142]
de Moura et al., 2011 Syntheticmimotope Loxosceles intermedia
Dermonecrotic
toxin LiD1 Rabbit antiserum L. intermedia venom
Dermonecrosis,
hemotoxicity [138]
Mendes et al., 2013 Recombinant toxin Loxosceles intermedia Dermonecrotictoxin LiD1
Rabbit antiserum
and IgG rLiD1
Dermonecrosis,
hemotoxicity [131]
Magalhães et al., 2013 Recombinant toxin Loxosceles gaucho Phospholipase D Rabbit antiserum LgRec1 and L. gauchovenom
Dermonecrosis,
local reaction [124]
Figueiredo et al., 2014 Recombinant toxin
Loxosceles intermedia,
Loxosceles laeta, and
Loxosceles gaucho
Sphingomyelinase
D Equine antiserum
L. intermedia, L. gaucho
and L. laeta venom Dermonecrosis [132]
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Dias-Lopes et al., 2014 Recombinant toxin
Loxosceles intermedia,
Loxosceles laeta, and
Loxosceles gaucho
Sphingomyelinase
D Murine IgG rLiD1
Dermonecrosis,
hemotoxicity, and
edema
[133]
Duarte et al., 2015 Recombinant toxin Loxosceles intermedia andLoxosceles laeta
Dermonecrotic
toxin LiD1 Equine antiserum
L. intermedia and L. laeta
venom
Dermonecrosis,
hemotoxicity [134]
Oliveira et al., 2016 Recombinant toxin Loxosceles intermedia SphingomyelinaseD (SMD) Murine antiserum
rSMDs, L. reclusa, L.
boneti, and L. laeta
venom
Lethality [135]
Lima et al., 2018 Recombinant toxin Loxosceles intermedia andLoxosceles laeta
Loxosceles
astacin-like
protease 1,
hyaluronidases,
SMase-I
Rabbit antiserum L. intermedia venom Lethality [125]
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4. Alternative Venom-Dependent Immunization Approaches
Other than venom-independent strategies, immunization approaches utilizing whole venom,
venom-derived toxin fractions, or purified toxins from venom that have been chemically deactivated
(toxoids) have also been investigated. Within the venom-dependent approaches, novel delivery
systems, adjuvants, and detoxification strategies have been introduced to enhance immune responses
and antibody neutralization capacity. In relation to delivery systems, already by 1985, New and
colleagues employed sphingomyelin-cholesterol liposomes to encapsulate Echis carinatus snake venom,
in order to raise an efficacious immune response in mice, rabbits, and sheep [143]. Other studies
also utilized liposomes with successful results [77,144–149]. For instance, in 1988, Laing et al.
encapsulated E. carinatus snake venom in sphingomyelin-cholesterol liposomes, and utilized these
to immunize mice [144]. Likewise, Freitas et al. reported immunization of mice and rabbits with
encapsulated Crotalus durissus snake venom, providing better protection than antiserum generated
by conventional methods (i.e., using Freund’s complete adjuvant), whilst also using 3 times lower
quantity of antigen [145]. In 1991, Chávez-Olórtegui encapsulated Tityus serrulatus scorpion venom
in sphingomyelin-cholesterol liposomes and used these for immunization of mice, which yielded
an antiserum that provided protection in 3 out of 4 naïve mice, when these were challenged
with T. serrulatus scorpion venom [146]. In 1993, Laing & Theakston demonstrated protection in
immunized mice against 4.3 LD50s (subcutaneous route) of E. ocellatus venom after immunization with
venom and lipopolysaccharide (LPS) encapsulated in membrane-stabilized reverse phase evaporation
liposomes [147]. Fonseca et al. also reported immunization of mice with encapsulated T. serrulatus
scorpion venom, providing antiserum with neutralization capacity of up to 3 LD50s (subcutaneous
route) against Tst-G50 in naïve mice [148].
Other venom-dependent immunization strategies that have been investigated include the utilization
of cross-linked chitosan, calcium-alginate, or poly (D,L-lactide) polymer nanoparticles [150–153].
Cross-linked chitosan nanoparticles were used to encapsulate T. serrulatus scorpion venom for
immunization of mice, resulting in antigen-specific murine antiserum with IgG titers equal to antisera
raised by immunization using an aluminum hydroxide adjuvant [150]. Similar results were achieved
by encapsulating Bothrops jararaca and B. erythromelas snake venom [153], and in another study,
calcium-alginate nanoparticles were used to encapsulate A. australis hector scorpion venom and applied for
immunization of rabbits. The immunized rabbits were protected when challenged subcutaneously with 6
LD50s of A. australis hector scorpion venom [151]. Lastly, lethality was reported neutralized in naïve mice,
when pre-incubating whole venom with murine antiserum from different mice immunized with either
A. australis hector (258 µg venom neutralized per mL antiserum) or Buthus occitanus tunetanus (186 µg
venom neutralized per mL antiserum) scorpion venoms and injected by the intracerebroventricular route,
where immunogens were encapsulated in poly (D,L-lactide) polymers [152]. Variations in the design of
emulsions used as adjuvants have also proven to impact the immune response of animals towards snake
venoms [154]. As such, optimization of immunization strategies involves the study of immunological
modulation of some venoms affecting the response to other venoms, e.g., when co-immunizing with
B. asper and Lachesis stenophrys snake venoms (see for example [155]). Such knowledge allows for the
improved design of immunization protocols, whereby different venoms are injected into animals at
different times to avoid such negative modulation.
A third venom-dependent approach that has been investigated has included chemical deactivation
of whole venom or toxin fractions used to generate antiserum with an increased neutralization
capacity, by enabling higher immunization dosages due to lowered toxicity. This deactivation has been
mediated by gamma radiation [156–159], reaction with glutaraldehyde [160–163], iodination [164,165],
alkylation [166], or reaction with formaldehyde [119]. In 1998, very high neutralization capacities
were reported by Heneine & Heneine, who used rabbit antiserum to neutralize up to 30 LD50s of
T. serrulatus scorpion venom in vitro [165]. Likewise, C. durissus terrificus snake venom was also
iodinated and used for immunization, yielding horse antiserum that protected naïve mice against
a challenge of 1.33 mg of C. durissus terrificus snake venom. In the same study, B. jararaca snake
Toxins 2018, 10, 452 21 of 37
venom was also iodinated and used for immunization of horses, yielding an antivenom that could
neutralize 13.7 mg of B. jararaca snake venom per mL in naïve mice [165]. These impressive numbers
were obtained by abrogating the toxicity of the antigen by gradual iodination, ensuring iodination
of tyrosine and histidine residues. The iodination did not oxidize side chains of other amino acids,
e.g., indole side chains of tryptophan residues, which may otherwise bring unwanted side effects, such
as lowered immunogenicity or antibodies specific against non-native toxins. In this way, Heneine &
Heneine obtained detoxified monomeric T. serrulatus toxins with assumed conserved epitopes, without
experiencing protein aggregation [165].
5. Alternative Immunization Approaches from Other Research Fields
In other fields, many new immunization or vaccination approaches have been investigated, which
could be used as inspiration for antivenom development, with a few selected examples provided in the
following. One approach involves the utilization of extracellular vesicles as a novel delivery system,
which can even contain MHC complexes when derived from dendritic cells [167]. It has also been
suggested that microvesicles normally carrying nucleic acids could be engineered to carry DNA for
immunization [167].
Another new delivery approach that has been studied utilizes bacterial ghosts [168–170], where
a native bacterial outer membrane (with or without LPS [170]) is utilized to encapsulate the desired
antigen. This was reported to be effective in inducing dendritic cell maturation in comparison to
LPS-based protocols [168], but may carry the risk of a too-low specific antibody titer. A third approach
has been to use nanocarriers to encapsulate an antigenic payload [91,171–173]. Active nanocarriers
are encapsulating nanoparticles with incorporated molecules for targeting purposes. A nanocarrier
could for instance incorporate an anti-DC-SIGN/CD209a antibody in the nanocarrier membrane,
targeting the vesicle for the mouse DC-SIGN/CD209a receptor on the surface of bone marrow-derived
dendritic cells (and macrophages). Schetters et al. reported in 2018 specific targeting of mDC-SIGN+
skin dendritic cells upon subcutaneous injection of an OVA-coupled anti-mDC-SIGN antibody, leading
to a strong anti-OVA response in vivo [174].
A fourth approach has involved conjugation of the desired antigen to virus-like particles
(VLPs), wherein different conjugation techniques have been tested. Fusion proteins and chemical
conjugation have been applied for this purpose, but even though much research has gone into this
field, few licensed VLP-based vaccines have been marketed [175]. The use of VLP-based vaccines
has been extensively reviewed elsewhere [175], but worth highlighting is the bacterial superglue
SpyTag/SpyCatcher conjugation method, which has already been used for the development of
candidate cancer [176] and malaria vaccines [177,178], among others. In 2014, this technology was
used to induce potent B and T cell responses by targeting dendritic cells with specific model antigens.
Here, functional synthetic vaccines were assembled by spontaneous conjugation of the targeting vector
(i.e., a dendritic cell-targeting antibody fragment fused to SpyTag) and the payload (i.e., an antigen
fused to SpyCatcher) [179].
A last approach to be mentioned here is the use of the adenylate cyclase toxin, CyaA, from
Bordetella pertussis, which mediates translocation of its genetically engineerable N-terminus into the
cytoplasmic site of eukaryotic cells with which it is in close proximity [180]. The CyaA toxin has
further been engineered to deliver antigens into APCs in vivo, after which epitopes of the antigen have
been reported to be confirmed displayed on the MHC I and II complexes of the targeted APCs [180].
In the future, CyaA can be combined with ex vivo dendrite cell vaccinations, where dendrites are
cultured ex vivo and re-introduced to the patient [181] (or re-introduced to animals for the production
of antivenom), for a more direct targeting approach, but may not be feasible for industrial scale-up in
antivenom manufacture.
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6. Biochemical, Bioinformatic, and Omics Tools that Could Aid Antivenom Development
Due to the complex composition of snake, scorpion, and spider venoms [33,182], the development
of next-generation antivenoms is not a trivial matter. Regardless of the developmental strategy
explored, it has become a necessity to establish which toxins researchers should focus on to achieve
neutralization of venom toxicity [42,183]. To achieve this, biochemical, bioinformatic, and omics tools
can be utilized to assist the process of antivenom development. The determination of key toxin targets
involves a two-step process. First, a detailed overview of venom composition(s) is required. For
this purpose, venom proteomics analysis (i.e., venomics) can be performed. Venomics allows for the
identification and quantification of venom components by combining venom fractionation using high
performance liquid chromatography and gel electrophoresis with mass spectrometry [40,47,184–187].
A more comprehensive venom profile can be obtained by integrating proteomics with genomic and
transcriptomic data [30,188], although mRNA transcription and protein expression levels do not
always correlate well [189]. Second, venomics data should be complemented with in vivo toxicity
studies of each toxin or venom fraction (i.e., toxicovenomics) to determine which components are
crucial for toxicity (Figure 3a) [190–192]. Using both venomics and toxicovenomics data, it is possible
to select specific key toxins based on their relative medical importance [42], and exclusively use these
to immunize animals.
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development. (a) Toxicovenomics: Venom composition is determined through venomics. Here,
venom is fractionat d by rev r ed-phas high-performanc liquid chromatography (RP-HPLC).
Subsequently, components of each venom fraction are identified by combining sodium dodecyl
sulfate-polyacrylamide gel electrophoresis (SDS-PAGE) and mass spectrometry (MS) analysis.
The toxicity of each venom fraction is evaluated in vivo to identify the medically relevant components
an antivenom should target. (b) Bioinformatics: Online resources can be used for in silico prediction of
epitopic elements and regions of homology from toxin sequences. Predicted epitopes and homologous
regions can then be utilized to generate multi-epitopic strings or consensus toxin sequences, respectively.
Such strategies aim at generating an immune response against multiple toxins using a single molecule
or to generate cross-reactive antibodies. (c) Antivenomics: This approach is employed to assess
antivenom reactivity and cross-reactivity based on immunoaffinity. By comparing the chromatographic
profiles of whole venom, unbound, and bound venom components, it is possible to discriminate
between venom fractions recognized and not recognized by antivenom antibodies. (d) High-density
peptide microarray technology: Short overlapping peptides from toxin amino acid sequences are
synthesized to study epitope-paratope interactions at an amino acid level by incubating the peptides
with antivenom antibodies. This strategy can be used to map epitopes or to assess antivenom reactivity
and cross-reactivity in a high-throughput manner.
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In search for key toxin targets, nowadays, numerous web servers for in silico prediction of
continuous and/or discontinuous epitopic elements have been developed (reviewed in [193–200]).
Based on either amino acid sequence analysis [201–208] or 3D-structural data [205,209–212], these
bioinformatic resources circumvent the expensive and time-consuming experimental procedures
previously employed for epitope mapping (Figure 3b). Localizing the immunogenic region of toxins
may allow for the synthesis of small peptides that could be used as synthetic epitopes for immunization.
Generally, neutralizing antibodies target epitopes that are three-dimensional structures that may
contain discontinuous epitopic elements [213]. However, some continuous epitopic elements are
still able to raise a protective immune response, as extensively exemplified by the studies reported
in Tables 1–3. In addition, shortening the size of the required antigen has opened the possibility of
generating recombinant epitope strings, in which immunization with a single molecule can give rise to
an immune response against multiple toxins [66,72,125]. Bioinformatic tools have also been applied
for identification of regions of homology between toxins belonging to the same family to determine
consensus toxin sequences [75,83]. Immunization with proteins derived from consensus sequences
aims towards generating cross-reactive antibodies (i.e., antibodies with the ability to recognize multiple
structurally similar toxins), ideally with cross-neutralization potential.
Cross-neutralizing antibodies are of utmost value, since they could be used to formulate
polyvalent antivenoms [30]. Besides the classical ELISA and enzymatic neutralization assays
employed for in vitro assessment of antivenom reactivity and cross-reactivity, more recently,
antivenomics has been employed for this purpose (Figure 3c). Basically, whole venom is passed
through a chromatographic column to which antivenom antibodies have been immobilized to.
Due to immunoaffinity, venom components recognized by antivenom antibodies are captured.
Therefore, by comparing the chromatographic profiles of whole venom, unbound, and bound venom
components, antivenomics can be used to determine which toxins the antivenom has the capacity
to bind [26,40,214–217]. Despite providing a detailed overview of the antivenom’s reactivity against
individual venom toxins, this strategy does not give precise information about the epitopic elements
involved in toxin-antibody interactions. In order to increase the resolution of epitope-paratope
interactions, high-density peptide microarray technology has recently been implemented in antivenom
research (Figure 3d). With this technology, the immunoreactivity of antivenoms against numerous
continuous epitopic elements derived from toxin sequences can be evaluated at an amino acid
level in a high-throughput manner [218–220]. Although cross-neutralization strictly needs to be
assessed in in vivo studies, antivenomics and high-density peptide microarray technology allow
for comprehensive analysis of antivenom cross-reactivity in a rapid and relatively inexpensive
way [30]. These tools may thus provide important guidance for directing the development of novel
antivenoms [30].
7. Conclusions
Improving the efficacy, safety, and affordability of antivenoms against animal envenomings
should be a key priority to enable better treatment of these diseases that particularly affect
impoverished victims in the rural tropics [12,221–224]. In the far future, a possibility may exist
for introducing novel antivenom products based on recombinantly produced antibodies or small
molecule inhibitors [35,36,225,226]. However, immediate improvements are also warranted, where
innovative, venom-independent immunization approaches offer the potential of quick adaptability, as
they are compatible with existing antivenom manufacturing setups. In addition, by circumventing the
need for venom in antivenom manufacture, the complications associated with animal captivity and
venom collection are to some extent limited.
Antivenom development by means of novel immunization approaches has been possible due
to the growing knowledge on venom compositions and toxicity obtained through different omics
technologies and other biotechnological tools, such as epitope mapping and recombinant expression
of heterologous proteins. Such approaches could particularly be used to improve efficacy (higher
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therapeutic antibody titers) [33] and to broaden the neutralization capacity of antivenoms to cover
species for which none of the currently available antivenoms work [227]. Improving these properties
may in turn lead to improved affordability for envenomed victims, as fewer antivenom vials with
a higher content of therapeutic antibodies would be needed to treat an envenoming. Moreover,
broadening the neutralization capacity of antivenoms could possibly warrant larger manufacturing
outputs, thereby decreasing cost of manufacture per vial. However, despite the numerous accounts
of the successful use of novel immunization strategies reported by different antivenom research
laboratories, very few of these strategies have found their way to the industrial setting. In the future,
the possibility also exists that a combination of innovative immunization strategies with transgenic
animals expressing the human antibody repertoire [228–231] could be employed in antivenom
manufacture. This may not improve efficacy or affordability, however, it may indeed provide safer
antivenoms, as the therapeutic antibodies would be of human, rather than animal origin. Improving
safety may even allow for earlier administration of antivenom to victims, which could possibly improve
treatment and recovery, due to a lowered risk of adverse reactions.
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